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Abstract
Balamuthia mandrillaris , a free-living ameba, causes rare but frequently fatal granulomatous 
amebic encephalitis (GAE). Few patients have survived after receiving experimental drug 
combinations, with or without brain lesion excisions. Some GAE survivors have been treated with 
a multi-drug regimen including miltefosine, an investigational anti-leishmanial agent with in vitro 
amebacidal activity. Miltefosine dosing for GAE has been based on leishmaniasis dosing because 
no data exist in humans concerning its pharmacologic distribution in the central nervous system. 
We describe results of limited cerebrospinal fluid (CSF) and serum drug level testing performed 
during clinical management of a child with fatal GAE who was treated with a multiple drug 
regimen including miltefosine. Brain biopsy specimens, CSF, and sera were tested for B. 
mandrillaris using multiple techniques, including culture, real-time polymerase chain reaction, 
immunohistochemical techniques, and serology. CSF and serum miltefosine levels were 
determined using a liquid chromatography method coupled to tandem mass spectrometry. The 
CSF miltefosine concentration on hospital admission Day 12 was 0.4 μg/mL. The serum 
miltefosine concentration on Day 37, about 80 hours post-miltefosine treatment, was 15.3 μg/mL. 
These are the first results confirming some blood-brain barrier penetration by miltefosine in a 
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human, although with low-level CSF accumulation. Further evaluation of brain parenchyma 
penetration is required to determine optimal miltefosine dosing for Balamuthia GAE, balanced 
with the drug’s toxicity profile. Additionally, the Balamuthia isolate was evaluated by real-time 
PCR, demonstrating genetic variability in18S rRNA sequences and possibly signaling the first 
identification of multiple Balamuthia strains with varying pathogenicities.
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Introduction
Balamuthia mandrillaris, a free-living ameba, has been isolated from soil (Schuster et al. 
2003; Dunnebacke et al. 2004; Niyyati et al. 2009) and its DNA has been identified in dust 
by polymerase chain reaction (PCR) (Ahmad et al. 2011). It may also be present in water, 
having been identified in dogs in contact with stagnant water (Foreman et al. 2004; Finnin et 
al. 2007). In the United States, the most common disease caused by Balamuthia infections is 
granulomatous amebic encephalitis (GAE), which in a minority of cases is preceded by or 
concurrent with the development of Balamuthia-induced skin lesions (CDC unpublished 
data). It is likely transmitted by inhalation of airborne cysts or by direct contamination 
through broken skin. Once Balamuthia enters the body, it is believed to spread 
hematogenously into the central nervous system (CNS) by breaching the blood-brain barrier 
(Visvesvara et al. 2011; Schuster et al. 2009; Reed et al. 1997). GAE occurs in both 
immunocompetent and immunocompromised persons of all ages, although Balamuthia GAE 
does appear to be more common among persons of Hispanic ethnicity (Visvesvara et al. 
2011; Schuster et al. 2009, Schuster et al. 2004).
GAE is usually a chronic disease with a prodromal period apparently lasting for several 
weeks to months. Initial signs and symptoms can include headache, neck stiffness, 
photophobia, vomiting, personality changes, and tonic-clonic seizures (Visvesvara et al. 
2011). More than 200 GAE cases have been reported worldwide (Visvesvara et al. 2011; 
Schuster et al. 2009). Timely GAE diagnosis is difficult, particularly because of nonspecific 
symptoms mimicking other types of encephalitis and lack of physician awareness of this 
disease. Therefore, other cases have likely occurred that were either undiagnosed or 
misdiagnosed.
Most GAE cases are fatal. Diagnosis is usually made by histochemical methods on biopsied 
brain tissue obtained late in the clinical course or at autopsy (Visvesvara et al. 2011). 
Nevertheless, a few patients have survived after biopsies (with or without complete excision 
of brain lesions) and subsequent treatment with experimental combinations of drugs, 
including pentamidine isethionate, fluconazole, flucytosine (5-fluorocytosine), sulfadiazine, 
and a macrolide (azithromycin or clarithromycin) (Deetz et al. 2003; Jung et al. 2004; Bravo 
et al. 2011; Cary et al. 2010). Miltefosine, an anti-protozoal drug used to treat visceral and 
cutaneous leishmaniasis, has also shown promise in treating GAE in combination with other 
anti-amebic drugs (Bravo et al. 2011; Martínez et al. 2010; Centers for Disease Control and 
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Prevention 2010). Miltefosine, a drug approved by the U.S. Food and Drug Administration 
(FDA) for the treatment of leishmaniasis (Food and Drug Administration 2015), is not sold 
in the United States but is available from the Centers for Disease Control and Prevention 
(CDC) for the treatment of free-living amebae infections under an expanded-access 
investigational new drug protocol in effect with the FDA (Centers for Disease Control and 
Prevention 2013). However, appropriate miltefosine dosing for GAE treatment has not been 
established and currently follows dosing regimens recommended for leishmaniasis 
treatment, which do not account for blood-brain barrier penetration or brain parenchyma 
accumulation because leishmaniasis is only rarely associated with neurologic pathology 
(Petersen and Greenlee 2011). Although miltefosine CNS penetration has been demonstrated 
in rats (Marschner et al. 1992), no data on CNS distribution in humans exists to guide GAE 
dosing decisions.
We present a case report of a child with fatal Balamuthia GAE and the first data from drug 
level testing performed in the course of clinical management that demonstrate blood-brain 
barrier penetration of miltefosine in a human.
Case report
An 11-year-old Texas boy of Hispanic ethnicity was hospitalized one August with a 3-week 
history of intermittent nausea, vomiting, progressive lethargy, clumsiness, and right-sided 
weakness resulting in a fall the day before admission. In retrospect, his parents noted 
neurologic changes dating back to April when he developed altered penmanship and 
problems reading and conversing; additionally, his grades slipped during the last 9 weeks of 
the school year and he experienced intermittent vomiting throughout most of the summer. 
The patient never complained of headaches or visual changes. His past medical history was 
otherwise unremarkable. He reportedly liked to dig in soil looking for artifacts, like 
arrowheads.
On admission Day 1, magnetic resonance imaging (MRI) of the brain revealed a nonspecific 
multifocal process predominantly involving the left cerebral hemisphere in the temporal and 
frontal lobes with severe edema and mass effect resulting in a midline shift (Figure 1). A 
tumor was suspected so a brain biopsy was performed on Day 2 and an extra-ventricular 
drain (EVD) was placed to monitor intracranial pressure post-operatively. Hematoxylin and 
eosin (H&E)-stained tissue sections showed amebic trophozoites and GAE was diagnosed; 
the patient was given anti-amebic chemotherapy beginning on Day 3. Table 1 summarizes 
the patient’s multi-drug regimen by hospital day. Indirect immunofluorescence testing (IFA) 
and real-time PCR performed at CDC later identified the amebae as Balamuthia 
mandrillaris. The patient also had an elevated anti-Balamuthia serum titer initially 1:64, 
considered positive for Balamuthia exposure (Schuster et al. 2006b), but rising to 1:256 later 
in the course of illness.
During the week following hospitalization, the patient became febrile and had increased 
nausea and vomiting. On Day 5, he had a right-sided focal seizure and received 
anticonvulsant drugs. On Day 6, he developed twitching in his hands and feet; an 
electroencephalogram showed no focal seizure activity. He also developed a mild right 
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hemiparesis and was more lethargic but still arousable, alert, and oriented. Miltefosine was 
started on Day 7. On Day 8, a repeat MRI revealed a diminished mass effect and midline 
shift with a mild reduction in lesion enhancement but with extensive areas of edema 
remaining and an acute left putamen lacunar infarct. His clinical condition remained fairly 
stable for several days and his right-sided weakness and twitching remained unchanged. 
However, by Day 20, he had newly developed double vision and another MRI that day 
showed a new lesion in the left temporal occipital white matter, although he had reduced 
edema and a resolution of the previous midline shift. Approximately 3 weeks post-
admission, his mental and neurologic status worsened significantly and he developed 
pancreatitis, renal impairment, myoglobinurea, and diarrhea. A MRI brain scan on Day 26 
showed multiple new foci in the white matter. By Day 32, he had complete right 
hemiparesis, could say only a few words and follow simple commands, had lost his gag 
reflex, and had developed aspiration pneumonia. Miltefosine was discontinued on Day 34 
(see Table 1). He received a tracheostomy about 5.5 weeks post-admission but never 
regained full alertness after post-operative sedation was lifted. Follow-up MRIs revealed 
progressing multifocal lesions in the right temporal/parietal lobe, left parietal lobe/thalamus, 
posterior fossa, and cerebellum. He was placed in palliative care on Day 49 and by Day 54 
showed very little spontaneous respiratory effort. He was pronounced dead 61 days post-
admission.
Materials and methods
Several specimens were sent to CDC for further testing, including brain tissue removed at 
biopsy and autopsy, and cerebrospinal fluid (CSF) and sera obtained during the clinical 
course. CSF and a portion of fresh brain tissue (macerated) were separately inoculated into 
human lung fibroblast (HLF) monolayers. The HLF cell cultures were sub-cultured 
periodically and amebae were harvested and stored at −80°C. The amebae stored at −80°C 
were thawed and disrupted and the resulting protein antigens were subjected to SDS-PAGE 
(Kucerova et al. 2011). Separated proteins were silver stained and compared with protein 
profiles of other isolates (Kucerova et al. 2011). Real-time PCR (Qvarnstrom et al. 2006) 
was performed on DNA from brain tissue, CSF and cultured amebae, extracted using the 
DNeasy tissue and blood kit (QIAGEN). Mitochondrial and nuclear small subunit ribosomal 
genes were amplified and sequenced as previously described (Booton et al. 2003a; Booton et 
al. 2003b). The mitochondrial gene (16S rRNA) was amplified twice and Sanger sequenced 
in both directions, resulting in 2- to 6-fold sequencing coverage at all positions. The PCR 
product from the nuclear gene (18S rRNA) was cloned as described elsewhere since it could 
not be sequenced directly due to overlapping peaks in the chromatograms (Qvarnstrom 
2013). Two clones were sequenced with at least 4-fold coverage at all positions; the two 
clones differed in just two positions towards the end of the gene. Consensus DNA sequences 
from the 18S and the 16S rRNA genes were deposited in GenBank with accession numbers 
JX524850 and JX524851, respectively. Formalin-fixed tissues from brain, optic nerve, 
lungs, liver, pancreas, and spleen were embedded in paraffin and sectioned. Sections were 
either stained with H&E or reacted with rabbit anti-Balamuthia antiserum (IFA) as 
described previously (Visvesvara et al. 1990) and examined using an Olympus BX-60 
microscope. Anti-Acanthamoeba serum served as a negative control because anti-
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Balamuthia antibodies do not cross react with anti-Acanthamoeba antibodies (Kucerova et 
al. 2011; Huang et al. 1999; Kiderlen et al. 2009). As with brain tissue, CSF was also 
cultured (Visvesvara et al. 1990; Visvesvara et al. 1993) and tested by real-time PCR. 
Multiple serum samples were tested for anti-Balamuthia antibodies by IFA (Schuster et al. 
2006b). Miltefosine levels in CSF and serum samples were analyzed by a validated liquid 
chromatography method coupled to tandem mass spectrometry (LC-MS/MS) with slight 
adaptations (Dorlo et al. 2008a). These samples were diluted (1:20) in blank human sodium 
EDTA plasma (Bioreclamation Inc., Hicksville, NY, USA) and further processed as 
previously described (Dorlo et al. 2008a). Samples were quantified based on a calibration 
line (4–2000 ng/mL) in human plasma. After sample preparation with phenyl-based solid 
phase extraction (SPE) and chromatographic separation on a Gemini C18 column (150 mm × 
4.6 mm, 5 μm) using 10mM NH4OH in methanol: water (95:5, v/v) as a mobile phase, 
samples were analyzed employing an API365 triple quadrupole mass spectrometer (Sciex, 
Thornhill, ON, Canada). Accuracy and precision were within ±15% deviation on all 
concentration levels and the lower limit of quantitation (in plasma) was 4 ng/mL (Dorlo et 
al. 2008a).
Results
Balamuthia began to be noticeable within one week in the HLF cell cultures inoculated with 
CSF and brain tissue. Amebae consumed, multiplied, and destroyed the HLF monolayer 
initially within two weeks and thereafter within three days on new platings, depending upon 
the numbers of amebae inoculated. Amebae converted to cysts when all of the monolayer 
was consumed. Both trophozoites and cysts of the isolate, designated as CDC:V630, were 
considerably smaller than the index Balamuthia organism originally isolated from a baboon 
brain (Visvesvara et al. 1990). However, they were morphologically similar to this index 
organism and other isolates of Balamuthia. Silver-stained protein profiles of cultured 
amebae revealed a complex pattern and produced major bands ranging from 200 to 10 kDa, 
but were more or less similar to that of the index isolate (Visvesvara et al. 1990).
Brain tissue and CSF from the patient, as well as the CDC:V630 culture, tested positive for 
B. mandrillaris in a real-time PCR assay developed to detect pathogenic free-living amebae 
in clinical specimens. On further molecular examination of the CDC:V630 culture, the 
mitochondrial small subunit ribosomal gene (16S rRNA) fragment was 1,075 base pairs in 
length and exhibited 98.6%–99.5% sequence similarity to corresponding sequences from 
other isolates of B. mandrillaris, with the highest similarity score to the V451 strain isolated 
previously (Booton et al. 2003a). This degree of variation is within the range previously 
found among B. mandrillaris 16S rRNA genes (Booton et al. 2003a). However, the nuclear 
small subunit ribosomal gene (18S rRNA) showed sequence divergence from existing 
sequences in the GenBank database (http://www.ncbi.nlm.nih.gov/genbank/index.html); the 
V630 isolate differed in 20 out of 1,969 nucleotide positions (including 11 transitions, 4 
transversions, and 5 indels) from the other B. mandrillaris isolates in GenBank (Figure 2).
On microscopic examination of H&E-stained sections, the brain and optic nerve appeared 
necrotic and amebae characterized by single nuclei were seen interspersed with degraded 
tissue (Figure 3a). Intense necrotic inflammation was evident with large numbers of 
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lymphocytes and polymorphonuclear leukocytes. Abundant amebae were seen in the 
necrotic optic nerve. Cysts were not evident in the tissue sections. The tissue sections 
examined by IFA reacted intensely with the rabbit anti-B. mandrillaris serum and produced 
fluorescence (Figure 3b). Negative reaction was seen with the rabbit anti-Acanthamoeba 
serum. Sections of the lung stained with H&E showed inflammation but amebae were not 
readily seen. However, the anti-Balamuthia-treated lung sections revealed a couple of foci 
of intense fluorescence and closer examination revealed a few glowing amebae (Figure 3c–
d). All other tissue sections were negative for amebae.
The patient’s serum samples produced high IFA titers for Balamuthia (from 1:64 to 1:256). 
Serum titers for anti-Balamuthia antibodies range from none to about 1:32 in patients 
without Balamuthia GAE and a titer of 1:64 or higher is considered a positive immune 
response (Schuster et al. 2006b).
Mass spectrometry analyses of miltefosine concentrations in the CSF and serum are 
summarized in Table 2. From Days 7–34, the patient received 50 mg miltefosine per 
nasogastric tube (NG) twice daily, corresponding to 2.65 mg/kg/day. On Day 12, miltefosine 
was first detected on analysis of ventricular CSF collected in the external bag of the EVD 
placed on Day 2 following the brain biopsy. The EVD was removed on admission Day 12 
and thereafter no further CSF/ventricular fluid samples were available for testing. The only 
serum sample was tested for miltefosine on Day 37, about 80 hours after termination of 
miltefosine treatment when the patient had developed acute renal insufficiency (creatinine 
4.2 mg/dL, BUN 87 mg/dL) and pancreatitis, presumed to be due to pentamidine.
Discussion
B. mandrillaris is the only known species of the genus Balamuthia (Visvesvara et al. 2011). 
In our patient, the nuclear small subunit ribosomal gene (18S rRNA) of his isolate 
(CDC:V630) showed quite a few sequence divergences from existing sequences in 
GenBank. This was unexpected since all previously determined 18S rRNA sequences from 
B. mandrillaris have been 100% identical, indicating that there is more DNA sequence 
divergence within the Balamuthia genus than previously thought and that the 16S rRNA 
gene may not be the best locus to explore that variability. Furthermore, this isolate was 
considerably smaller in size compared to other B. mandrillaris isolates. These observations 
might signal the presence of multiple strains of B. mandrillaris with varying pathogenicities, 
which could help explain the elevated anti-Balamuthia antibody levels observed in some 
asymptomatic but presumably exposed individuals in Africa and Australia (Huang et al. 
1999; Kiderlen et al. 2009).
When Balamuthia exposure results in GAE, it is generally fatal. Many drug combinations 
have been administered to Balamuthia GAE patients but few have recovered (Deetz et al. 
2003; Jung et al. 2004; Bravo et al. 2011; Cary et al. 2010; Martínez et al. 2010; Centers for 
Disease Control and Prevention 2010) and effective treatment has not yet been established. 
Our patient was treated with corticosteroids and multiple antimicrobials. One of the 
antimicrobials given to our patient was miltefosine. Miltefosine is an orally administered 
alkylphosphocholine compound that was originally developed as an anti-cancer drug (Eibl 
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and Unger 1990). However, for infectious diseases, it has mainly been used as an anti-
protozoal drug and the World Health Organization (WHO) lists miltefosine in its essential 
medicines formulary as an anti-leishmaniasis medicine (World Health Organization, 2015). 
Miltefosine is currently approved for treatment of leishmaniasis in the United States by FDA 
(U.S. Food and Drug Administration, 2015). Recently, miltefosine has not only shown good 
in vitro activity against free-living amebae but has also appeared promising in treating 
patients with Balamuthia GAE, in combination with other drugs (Bravo et al., 2011; 
Martínez et al. 2010; Centers for Disease Control and Prevention 2010). Our patient 
received 53 doses of miltefosine (50 mg BID) over 26.5 days (Days 7–34). After an initial 
stabilization of symptoms, miltefosine was discontinued 27 days prior to death due to 
progression of neurologic deterioration, development of multiple organ dysfunction due to 
presumed drug toxicities, and uncertainty of the contributing role of miltefosine to these 
toxicities. At the time, no information was available in the literature about CNS penetration 
of oral miltefosine to guide drug dosing during his clinical course. Drug level testing on 
available CSF and serum samples was therefore performed.
The presence of miltefosine in our patient’s CSF 5 days after initiation of miltefosine 
treatment indicated penetration of miltefosine through the blood-brain barrier, although 
disruption of the barrier due to Balamuthia infection could not be excluded. Moderate brain 
tissue penetration of miltefosine was previously demonstrated in rats (Marschner et al. 1992) 
but has never been evaluated in humans and was not evaluated directly in our patient. 
However, some conclusions can still be suggested with our limited CSF and serum samples. 
Our patient’s serum level approximately 80 hours after miltefosine discontinuation was 15.3 
μg/mL. Taking into account the known miltefosine initial elimination half-life of 
approximately 7 days (Dorlo et al. 2008b; Dorlo et al. 2012b), the extrapolated steady-state 
serum concentration at the time of miltefosine discontinuation would have approximated 
21.3 μg/mL. The in vitro minimum amebacidal concentration (MAC) of miltefosine for 
some Balamuthia isolates has been shown to be 16.3 μg/mL (40 μM), with variation in 
sensitivity between strains (Schuster et al. 2006a). Although this value might not be 
comparable between labs due to the use of different assay methodologies and is likely 
difficult to extrapolate to the in vivo situation, in particular because of the use of protein-rich 
culture media (Schuster and Visvesvara 1996), the approximated serum miltefosine level at 
the time of discontinuation exceeded this MAC. However, this MAC value must be 
interpreted with caution. Miltefosine is 95% protein-bound (Dorlo et al. 2008b, Dorlo et al. 
2012a). Consequently, only 5% of the total serum concentration represents free drug. If the 
pharmacodynamics of anti-amebic agents is similar to antibacterial agents, then only the free 
drug fraction would be expected to be pharmacologically active. The original in vitro MAC 
experiments used protein-rich culture media (Schuster and Visvesvara 1996) but did not 
account for the effects of potential protein binding in the MAC calculations. Therefore, the 
MAC represents the total miltefosine concentration, not the free miltefosine concentration, 
and cannot be used as a basis of comparison for the latter. Penetration of miltefosine from 
serum into CSF and brain parenchymal tissue is of additional and particular importance. The 
miltefosine CSF level in our patient on Day 12 after 9 doses (50 mg per dose) of the drug 
over 5 days was 0.4 μg/mL, a level much less than that expected to be efficacious in the 
treatment of Balamuthia infection. Assuming that the serum concentration was between 10–
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20 μg/mL on Day 12, given the 7-day half-life and the fact that steady state of the drug had 
not yet been reached, this suggests only 2–4% passage across the blood-brain-barrier. 
Further, depending upon the concentration of protein in CSF, the free drug level was likely 
substantially less than the total drug level achieved in CSF. While these results may suggest 
that miltefosine would not be effective in the treatment of meningitis (measured CSF levels), 
miltefosine might still be effective in treating encephalitis (unmeasured brain parenchymal 
levels) since the primary infection site for Balamuthia is brain parenchyma, not the 
meninges. There is precedence for other agents that pass poorly into CSF, such as 
macrolides, penetrating well into brain parenchyma (Nau et al. 2010; Jaruratanasirikul et al. 
1996). Despite our patient’s measured drug levels, miltefosine has shown promise in treating 
other patients with Balamuthia GAE, in combination with other drugs (Bravo et al., 2011; 
Martínez et al. 2010; Centers for Disease Control and Prevention 2010). It is possible that 
the observed success of miltefosine in reported GAE cases may be due to superior 
penetration into brain parenchyma when compared to CSF. Moreover, in addition to its 
direct amebacidal effects, previously demonstrated miltefosine immunomodulatory effects 
may also play a role (Wadhone et al. 2009).
Conclusion
Balamuthia GAE, while rare, continues to have devastating outcomes and high mortality. 
Even with rapid diagnosis and interventional therapy, our case was fatal. The ameba isolated 
and cultured from this patient differed in size and ribosomal DNA sequences from 
previously identified B. mandrillaris isolates, suggesting there may be multiple strains of B. 
mandrillaris that may affect pathogenicity and drug resistance. Further investigation of 
Balamuthia through strain typing and genome sequencing should be considered.
CSF drug level testing performed during clinical management of a child with fatal 
Balamuthia GAE demonstrated for the first time that miltefosine, an anti-leishmanial agent 
with in vitro amebacidal activity, penetrates the blood-brain barrier to a limited extent in a 
human. Although miltefosine might hold promise as an adjunct to the current experimental 
drug cocktail now used to treat Balamuthia GAE, more research is needed to find the most 
effective doses and optimal drug combination. Given our patient’s death after receiving 2.65 
mg/kg/day of miltefosine and considering that pediatric patients need a higher mg/kg dosage 
compared to adults to achieve a similar level of miltefosine exposure (Dorlo et al. 2012b), a 
higher daily miltefosine dosage might be considered in future Balamuthia GAE cases if the 
apparent moderate gastrointestinal and moderate liver toxicity caused by this drug can be 
controlled.
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Magnetic resonance imaging (MRI) of the brain during the patient’s clinical course. (a). 
Initial MRI on admission Day 1 revealed a nonspecific multifocal lesion involving the left 
frontal temporal lobe with surrounding edema and midline shift. (b). MRI on Day 8 revealed 
postoperative changes with diminished mass effect and midline shift. (c). MRI on Day 20 
(flair axial image) revealed a new lesion in left temporo-occipital white matter (arrow) and 
further reduction in edema with resolution of midline shift. (d). MRI on Day 26 (T1 sagittal 
image) revealed numerous new foci throughout the brain (arrows)
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Variable positions in the 18S rRNA gene sequences from Balamuthia mandrillaris isolates 
available in GenBank as of 2013. The alignment was made with ClustalW using Geneious 
v7.1.5. A dash (-) indicate an insertion/deletion. Total length of alignment was 1,973 base 
pairs. The isolate from the patient described in this report was designated as CDC:V630
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Hematoxylin and eosin (H&E) or indirect immunofluorescence (IFA) staining of tissue 
sections. (a) A section of brain stained with H&E—Balamuthia amebae are seen 
interspersed within the tissue at magnification X 100. (b) A similar section of brain reacted 
with anti-Balamuthia mandrillaris serum in the IFA test at magnification X 100. (c) IFA 
reactivity of Balamuthia amebae in a section of lung at magnification X 100 indicating 
dissemination of amebae into the lung. (d) A high power (magnification X 1,000) view of an 
ameba in the lung by IFA staining
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Table 1








Dexamethasone Day 1 25 days 4mg IV every 6 hours, slowly 
tapered
Anti-inflammatory drug for cerebral edema
Fosphenytioin Day 1 4 days 100 mg IV every 12 hours Anticonvulsant drug
Liposomal amphotericin B Day 2 3 days 380 mg IV daily (10 mg/kg/day) Anti-amebic drug; first administered at 
initial suspicion of GAE, discontinued in 
favor of more specific anti-Balamuthia 
therapy
Azithromycin Day 3 58 days 750 mg IV daily Anti-amebic drug
Fluconazole Day 3 58 days 400 mg IV daily Anti-amebic drug adjusted for renal 
insufficiency
5-fluorocytosine (5FC) Day 3 58 days 1000 to 1425 mg per nasogastric 
tube (NG) every 6 hours
Anti-amebic drug adjusted based on levels
Pentamidine Day 3 23 days 160 mg IV daily Anti-amebic drug discontinued due to 
pancreatitis and electrolyte problems
Sulfadiazine Day 3 58 days 500 mg PO and NG every 6 
hours
Anti-amebic drug
Levetiracetam Day 5 12 days 400mg IV every 12 hours Anticonvulsant drug
Miltefosine Day 7 26.5 days 50 mg NG twice daily (2.65 
mg/kg/day)
Anti-amebic drug discontinued prior to 
death due to progression of neurologic 
deterioration, development of multiple 
organ dysfunction due to presumed drug 
toxicities, and uncertainty of the 
contributing role of miltefosine to these 
toxicities
Phenobarbital Day 14 6 days 55 to 110 mg IV every 12 hours Anticonvulsant drug
Valproate Day 20 4 days 500 mg IV every 12 hours Anticonvulsant drug
Lorazapam Day 21 23 days 1.0–2.5 mg IV every 8 hrs, with 
additional doses as required
Anticonvulsant drug
Metronidazole Day 22 39 days 370 mg IV every 6 hours Anti-amebic drug for a new brain lesion 
discovered on MRI on Day 20
Thioridazine Day 26 35 days 15 mg NG twice daily Anti-psychotic drug and might also have 
anti-amebic activity
Methylprednisolone Day 47 14 days 20 mg IV every 6 hours Anti-inflammatory drug for cerebral edema
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Table 2
Miltefosine levels in the cerebrospinal fluid and serum of a patient with Balamuthia mandrillaris 
granulomatous amebic encephalitis, United States, 2010
Specimen Type Collection Date (Hospital Admission Day)




CSF Day 6 −1 0 (<LOD) c
CSF Day 6 −1 0 (<LOD) c
CSF Day 12 5 0.4
Serum Day 37 30 (about 80 hours after last dose) 15.3 d
a
First dose of miltefosine (50 mg twice daily) administered on Day 7 and last dose administered on Day 34.
b
Analyzed on API365 LC-MS/MS equipment; dilution of CSF and sample pretreatment using phenyl-based solid phase reaction.
c
LOD = Limit of detection; not determined for miltefosine in CSF but is probably below 20 ng/mL.
d
At this time, patient had developed acute renal insufficiency (creatinine 4.2 mg/dL, BUN 87 mg/dL) and pancreatitis presumed to be due to 
pentamidine.
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